Pedmarqsi is a medicine used in children aged 1 month to less than 18 years old to reduce the risk of hearing loss caused by the cancer medicine cisplatin when used to treat solid tumours that have not spread. Pedmarqsi contains the active substance sodium thiosulfate.
Therapeutic Indication
### Therapeutic indication Pedmarqsi is indicated for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to < 18 years of age with localised, non-metastatic, solid tumours.
Therapeutic Area (MeSH)
N/AATC Code
N/A
ATC Item
N/A
Pharmacotherapeutic Group
All other therapeutic products
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| sodium thiosulfate | N/A | 硫代硫酸钠 |
EMA Name
Pedmarqsi
Medicine Name
Pedmarqsi
Aliases
N/ANo risk management plan link.
